Home > Healthcare > Biotechnology > Biopharma > Carcinoembryonic Antigen (CEA) Market

Carcinoembryonic Antigen (CEA) Market Trends

Report ID: GMI427
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Carcinoembryonic Antigen Market Trends

Recent technological advancements in cancer diagnostics have shifted the focus toward improving CEA diagnostics, significantly driving market growth. These innovations have improved the sensitivity, specificity, and overall accuracy of CEA tests, enhancing their reliability and effectiveness in the early detection, monitoring, and prognosis of certain cancers, including colorectal, pancreatic, and gastric cancers, thereby bolstering market demand.

For example, Roche's Elecsys CEA immunoassay employs advanced electrochemiluminescence technology to deliver highly sensitive and specific results, even at low CEA concentrations. This innovation enables earlier cancer detection, improving patient prognosis and expanding the clinical utility of CEA tests.
Similarly, another significant advancement is the incorporation of multiplex assays, which allows for the simultaneous measurement of multiple biomarkers, including CEA. This multi-analyte approach provides a more comprehensive view of a patient's cancer status, improving diagnostic accuracy and offering more personalized treatment options.

Therefore, growing advancements in diagnostic technologies, increasing awareness about cancer screening, and improved healthcare infrastructure further contribute to market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global carcinoembryonic antigen industry was valued at USD 2.2 billion In 2023 and is projected to grow at a 6.3% CAGR from 2024 to 2032, driven by the increasing prevalence of various cancers, including colorectal, lung, and breast cancers.

The gastrointestinal cancer segment led the market with a 41.4% share in 2023 and is expected to maintain its dominance with a CAGR of 6.7% during the forecast period.

The U.S. market's prominence is attributed to its advanced healthcare infrastructure, a high prevalence of gastrointestinal cancers, and robust research initiatives. In 2023, the U.S. market in North America was valued at USD 830.1 million and is anticipated to show considerable growth over the analysis period.

Prominent players in the industry include Abcam Limited, AdvaCare Pharma, Aviva Systems Biology Corporation, Boster Biological Technology, Creative Diagnostics, Diazyme Laboratories Inc., F. Hoffmann-La Roche Ltd., Medix Biochemica, Omega Diagnostics Ltd., RayBiotech, Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated.